Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2026)

Adaptive Biotechnologies has disclosed Total Current Liabilities across 9 years of filings, most recently posting $87.0 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $87.0 million, down 0.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.0 million (down 0.91% YoY), and the FY2025 annual result was $89.9 million, down 8.3% from the prior year.
• Total Current Liabilities came in at $87.0 million for Q1 2026 at Adaptive Biotechnologies, down from $89.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $115.1 million in Q1 2022 to a low of $83.0 million in Q1 2024.
• The 5-year median for Total Current Liabilities is $90.1 million (2023), against an average of $94.4 million.
• Across the five-year window, Total Current Liabilities declined 21.7% in 2023 and grew 11.4% in 2024, its largest moves.
• Adaptive Biotechnologies' Total Current Liabilities stood at $109.8 million in 2022, then dropped by 19.83% to $88.0 million in 2023, then climbed by 11.4% to $98.1 million in 2024, then fell by 8.3% to $89.9 million in 2025, then retreated by 3.23% to $87.0 million in 2026.
• The last three Total Current Liabilities figures came in at $87.0 million (Q1 2026), $89.9 million (Q4 2025), and $83.4 million (Q3 2025), per Business Quant data.